EUVIMEDEUVIMED entdecken
Crossref

Physiologically Based Pharmacokinetic Modeling to Investigate the Disease‐Drug–Drug Interactions between Voriconazole and Nirmatrelvir/Ritonavir in COVID ‐19 Patients with CYP2C19 Phenotypes

Peile Wang iD, Shuaibing Liu iD, Jing Yang iD

Clinical Pharmacology & Therapeutics · 2024-08 · 116 (2) · 363-371

DOI: 10.1002/cpt.3222 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2024-03. Verfasst von Peile Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. Hauptthemen laut MEDLINE: Voriconazole, Cytochrome P-450 CYP2C19, Ritonavir, Drug Interactions. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Coronavirus disease 2019 (COVID‐19)‐associated pulmonary aspergillosis superinfection with cytokine storm is associated with increased mortality. This study aimed to establish a physiologically‐based pharmacokinetic (PK) model to investigate the disease‐drug–drug interactions between voriconazole and nirmatrelvir/ritonavir in patients with COVID‐19 with elevated interleukin‐6 (IL‐6) levels carrying various CYP2C19 phenotypes. The model was constructed and validated using PK data on voriconazole, ritonavir, and IL‐6, and was subsequently verified against clinical data from 78 patients with COVID‐19. As a result, the model predicted voriconazole, ritonavir, and IL‐6 PK parameters and drug–drug interaction‐related fold changes in healthy subjects and patients with COVID‐19 with acceptable prediction error, demonstrating its predictive capability. Simulations indicated ritonavir could increase voriconazole exposure to CYP2C19 intermediate and poor metabolizers rather than decrease it, in contrast to what is indicated in the drug package insert. However, the predicted ritonavir exposures were comparable across subjects. In patients with COVID‐19, both ritonavir and IL‐6 increased voriconazole trough concentrations, which may lead to CYP2C19 phenotype‐dependent overexposure. In conclusion, COVID‐19‐induced IL‐6 elevation and ritonavir increased voriconazole exposure, and the magnitude of interactions was influenced by CYP2C19 phenotype. Thus, caution is warranted when prescribing voriconazole concomitantly with Paxlovid in patients with COVID‐19.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VoriconazoleCytochrome P-450 CYP2C19RitonavirDrug InteractionsCOVID-19 Drug TreatmentPhenotypeAntifungal AgentsInterleukin-6Models, BiologicalHumansMaleFemaleMiddle AgedAdultAgedCOVID-19

Substanzen

VoriconazoleCytochrome P-450 CYP2C19RitonavirCYP2C19 protein, humanAntifungal AgentsInterleukin-6IL6 protein, human

Autor:innen und Institutionen

  • Department of Pharmacy, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Henan Key Laboratory of Precision Clinical Pharmacy, Zhengzhou University, Zhengzhou, China.
  • Henan Engineering Research Center for Application & Translation of Precision Clinical Pharmacy, Zhengzhou University, Zhengzhou, China.

ORCID-Profile: Peile Wang, Shuaibing Liu, Jing Yang

Zitieren

APA

Wang, P., Liu, S., & Yang, J. (2024). Physiologically Based Pharmacokinetic Modeling to Investigate the Disease‐Drug–Drug Interactions between Voriconazole and Nirmatrelvir/Ritonavir in COVID ‐19 Patients with CYP2C19 Phenotypes. Clinical Pharmacology & Therapeutics, 116(2), 363-371. https://doi.org/10.1002/cpt.3222

Vancouver

Wang P, Liu S, Yang J. Physiologically Based Pharmacokinetic Modeling to Investigate the Disease‐Drug–Drug Interactions between Voriconazole and Nirmatrelvir/Ritonavir in COVID ‐19 Patients with CYP2C19 Phenotypes. Clinical Pharmacology & Therapeutics. 2024;116(2):363-371. doi:10.1002/cpt.3222

BibTeX
@article{Wang2024,
  author = {Wang, Peile and Liu, Shuaibing and Yang, Jing},
  title = {Physiologically Based Pharmacokinetic Modeling to Investigate the Disease‐Drug–Drug Interactions between Voriconazole and Nirmatrelvir/Ritonavir in COVID ‐19 Patients with CYP2C19 Phenotypes},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2024},
  volume = {116},
  number = {2},
  pages = {363--371},
  doi = {10.1002/cpt.3222}
}
Kostenlos starten →